What is atherosclerosis?
Atherosclerosis is a potentially serious condition where arteries become narrowed with fatty substances called plaque.
Arteries are blood vessels that carry oxygen-rich blood to the heart and other parts of the body. If arteries become blocked and the blood flow to the heart and brain is restricted, then there is an increased risk of heart attacks, strokes and blood clots.
The consequence of this can lead to conditions such as coronary heart disease (CHD), which is a serious public health issue and a major cause of death in many countries worldwide.
Our aim is to address the unmet needs in the treatment of atherosclerosis and provide therapies that can provide a benefit to patient care.
PARTHENON clinical trials programme
PARTHENON’s overall objective is to enhance understanding of the role of ticagrelor in the treatment of atherothrombotic conditions. Four studies from the programme have completed with the final study set to read-out in Q4 2018.
During the course of the programme, over 85,000 patients across the global have taken part in the studies assisting to address unanswered questions in the management of atherothrombotic disease.
What we're working on
We are dedicating ourselves to researching and working on new treatments to advance the treatment of atherosclerosis
AZD-5718 (FLAP [arachidonate 5-lipoxygenase-activating protein] inhibitor) is a small molecule currently being investigated in a Phase I study in patients with coronary artery disease (CAD).
The ongoing STRENGTH (NCT02104817) trial, comprising 13,000 patients across 22 countries, will assess if omega-3-carboxylic acids in combination with statin medicines reduces CV morbidity and mortality in patients with mixed dyslipidaemia.
THEMIS (NCT01991795) is a global trial designed to evaluate the efficacy of ticagrelor for people with type-2 diabetes and coronary atherosclerosis, reinforcing AstraZeneca’s commitment to exploring the potential benefits of our medicines for high-risk patients.
The THEMIS trial is a Phase III, global, randomised, double-blind, event-driven trial evaluating the efficacy and safety of ticagrelor compared to placebo when administered for the prevention of major CV events in patients with type-2 diabetes and coronary atherosclerosis. Enrolment was completed in May 2016 with 19,349 patients randomised across 42 countries following the beginning of enrolment in November 2012.
Disease area resources
Secondary prevention in myocardial infarction
We are working to increase the level of awareness on the risks of myocardial infarction occurring following an initial CV event.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
- Mayo Clinic. Arteriosclerosis / atherosclerosis. Accessed 15 August 2017. http://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/symptoms-causes/dxc-20167022.
- National Heart, Lung and Blood Institute. What Is Coronary Heart Disease? Accessed 15 August 2017. https://www.nhlbi.nih.gov/health/health-topics/topics/cad.
- World Health Organization. Cardiovascular diseases (CVDs). Accessed 15 August. http://www.who.int/mediacentre/factsheets/fs317/en/.
Veeva ID: Z4-6505
Date of expiry: August 2018